Susquehanna International Group, LLP Tricida, Inc. Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.14 - $12.49 $18,689 - $1.67 Million	-133,495 Reduced 64.9%	72,200 $10,000
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $1.3 Million - $2.08 Million	153,032 Added 290.59%	205,695 $2.16 Million
Q2 2022 Aug 15, 2022	SELL	$7.31 - $11.85 $1.54 Million - $2.49 Million	-210,110 Reduced 79.96%	52,663 $510,000
Q1 2022 May 16, 2022	BUY	$7.35 - $10.63 $117,644 - $170,143	16,006 Added 6.49%	262,773 $2.16 Million
Q4 2021 Feb 14, 2022	BUY	$4.19 - $9.56 $377,694 - $861,757	90,142 Added 57.55%	246,767 $2.36 Million
Q3 2021 Nov 15, 2021	BUY	$3.56 - $4.64 $282,938 - $368,773	79,477 Added 103.02%	156,625 $727,000
Q2 2021 Aug 11, 2021	SELL	$3.95 - $5.41 $139,454 - $191,000	-35,305 Reduced 31.4%	77,148 $333,000
Q1 2021 May 17, 2021	BUY	$4.52 - $7.8 $195,630 - $337,591	43,281 Added 62.57%	112,453 $595,000
Q4 2020 Feb 16, 2021	BUY	$4.37 - $9.46 $54,000 - $116,897	12,357 Added 21.75%	69,172 $488,000
Q3 2020 Nov 16, 2020	BUY	$8.56 - $26.93 $423,137 - $1.33 Million	49,432 Added 669.54%	56,815 $515,000
Q2 2020 Aug 14, 2020	SELL	$21.21 - $31.55 $36,035 - $53,603	-1,699 Reduced 18.71%	7,383 $203,000
Q1 2020 May 15, 2020	BUY	$18.43 - $38.04 $167,381 - $345,479	9,082 New	9,082 $200,000
Q4 2019 Feb 14, 2020	SELL	$29.6 - $43.71 $312,516 - $461,490	-10,558 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$29.87 - $42.22 $52,630 - $74,391	1,762 Added 20.03%	10,558 $326,000
Q2 2019 Aug 16, 2019	BUY	$31.16 - $39.46 $274,083 - $347,090	8,796 New	8,796 $347,000
Q3 2018 Nov 14, 2018	SELL	$22.5 - $39.35 $281,992 - $493,173	-12,533 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$26.0 - $29.9 $325,858 - $374,736	12,533 New	12,533 $375,000

Others Institutions Holding TCDA

# of Institutions

Shares Held

30K

Call Options Held

124K

Put Options Held

46.5K

View Full List

About Tricida, Inc.

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

More about TCDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account